Accession Number ADA566503
Title Novel Drugs that Target ErbB2.
Publication Date May 2012
Media Count 51p
Personal Author S. Safe
Abstract Betulinic acid (BA) is relatively non-toxic in rodent studies and highly effective against melanoma in both in vivo and in vitro assays. Subsequent research in several laboratories indicates that BA inhibits growth of multiple tumor types including breast cancer. Studies in this laboratory show that BA inhibits prostate cancer cell and tumor growth in a xenograft model, and one of the underlying mechanisms of action is due to BA-induced proteasome-dependent degradation of specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4. These proteins are highly expressed in several different cancer cell lines and tumors, whereas Sp1 levels in non-tumor tissue of rodents and humans is relatively low and decreases with age. In this study, we used BA as a model to investigate the effect of Sp1, Sp3 and Sp4 downregulation on BT474 and MDA-MD-453 breast cancer cells that express the oncogene EGFR2 (ErbB2, HER2). The proposed research focused on the role of BA- induced Sp downregulation on cell and tumor growth, ErbB2 expression and the overall mechanisms associated with the anticancer activity of BA. We also investigated the role of BA in triple-negative MDA-MB-231 cells which do not express ErbB2.
Keywords Betulinic acid
Cancer
Cannabinols
Cells(Biology)
Drugs
Melanoma
Prostate cancer
Proteins
Surgical transplantation
Toxicity
Transcription(Genetics)


 
Source Agency Non Paid ADAS
NTIS Subject Category 57Q - Pharmacology & Pharmacological Chemistry
57S - Physiology
57E - Clinical Medicine
Corporate Author Texas A and M Univ., College Station.
Document Type Technical report
Title Note Final rept. 1 May 2010-30 Apr 2012.
NTIS Issue Number 1307
Contract Number W81XWH-10-1-0075

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader